400 related articles for article (PubMed ID: 21383766)
21. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
22. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
23. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.
Fionda C; Abruzzese MP; Zingoni A; Soriani A; Ricci B; Molfetta R; Paolini R; Santoni A; Cippitelli M
BMC Cancer; 2015 Jan; 15():17. PubMed ID: 25609078
[TBL] [Abstract][Full Text] [Related]
25. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract][Full Text] [Related]
26. DNAM-1 controls NK cell activation via an ITT-like motif.
Zhang Z; Wu N; Lu Y; Davidson D; Colonna M; Veillette A
J Exp Med; 2015 Nov; 212(12):2165-82. PubMed ID: 26552706
[TBL] [Abstract][Full Text] [Related]
27. Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.
Xiong P; Sang HW; Zhu M
Immunology; 2015 Nov; 146(3):369-78. PubMed ID: 26235210
[TBL] [Abstract][Full Text] [Related]
28. Expression of DNAM-1 (CD226) on inflammatory monocytes.
Vo AV; Takenaka E; Shibuya A; Shibuya K
Mol Immunol; 2016 Jan; 69():70-6. PubMed ID: 26675069
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands.
Tahara-Hanaoka S; Miyamoto A; Hara A; Honda S; Shibuya K; Shibuya A
Biochem Biophys Res Commun; 2005 Apr; 329(3):996-1000. PubMed ID: 15752754
[TBL] [Abstract][Full Text] [Related]
30. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
de Andrade LF; Smyth MJ; Martinet L
Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
[TBL] [Abstract][Full Text] [Related]
31. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
[TBL] [Abstract][Full Text] [Related]
33. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
[TBL] [Abstract][Full Text] [Related]
34. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterization of a novel anti-DNAM-1 monoclonal antibody.
Yamashita Y; Abe F; Hirochika R; Tahara-Hanaoka S; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):60-4. PubMed ID: 23600509
[TBL] [Abstract][Full Text] [Related]
36. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
37. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.
Campos C; López N; Pera A; Gordillo JJ; Hassouneh F; Tarazona R; Solana R
Biogerontology; 2015 Oct; 16(5):671-83. PubMed ID: 25991472
[TBL] [Abstract][Full Text] [Related]
38. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.
Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Sanchez-Correa B; Guerrero B; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Sanchez-Garcia J; Serrano J; Martin C; Duran E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764229
[No Abstract] [Full Text] [Related]
40. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
